Atomic AI Creates First Large Language Model Using Chemical Mapping Data to Optimize RNA Therapeutic Development
Retrieved on:
Friday, December 15, 2023
FDA, Other Health, Technology, Pharmaceutical, Infectious Diseases, Hospitals, Genetics, Artificial Intelligence, Clinical Trials, Cardiology, Science, Biotechnology, Other Science, Health, Research, Machine learning, Toxicity, Nucleic acid structure, Atomic, Patient, Multimedia, Vaccine, Data collection, Infection, Messenger, COVID-19, Therapy, Drug discovery, RNA, Cancer, BioRxiv, Conceptual model, Endoribonuclease-prepared siRNA, LLM, Phosphorus
Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, announced that the Company has created the first large language model (LLM) leveraging chemical mapping data.
Key Points:
- Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, announced that the Company has created the first large language model (LLM) leveraging chemical mapping data.
- In a preprint paper published on bioRxiv, Atomic AI describes its proprietary ATOM-1™ platform component, a foundation model that can accurately predict the structure and function of RNA and help dramatically improve development of RNA therapeutics.
- Due to this deficiency of “ground-truth” data, it has been challenging to optimize key RNA therapeutic characteristics, including stability, toxicity, and translational efficiency.
- “By building large datasets based on RNA nucleotide modifications and next-generation sequencing, the team at Atomic AI has created a first-of-its-kind RNA foundation model,” said Stephan Eismann, Ph.D., Founding Scientist and Machine Learning Lead at Atomic AI.